BC-003

BC-003 is an experimental dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy developed by Singapore-based BioCell Innovations. The therapy utilizes autologous T cells genetically engineered to express a dual-targeting CAR construct that simultaneously recognizes CD19 and CD20, two antigens predominantly expressed on the surface of B-cells. While the therapy is primarily designed for the treatment of B-cell malignancies, including relapsed and refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), some developer pipeline documentation associates the candidate with hepatocyte-related conditions. This association is noted in source material as a likely data extraction error or fabrication given the biological targets. BC-003 is currently in the discovery and early development phase.